Granules India Limited (NSE: GRANULES)
India
· Delayed Price · Currency is INR | Market Cap | 144.61B |
| Revenue (ttm) | 44.78B |
| Net Income (ttm) | 4.87B |
| Shares Out | n/a |
| EPS (ttm) | 20.09 |
| PE Ratio | 29.68 |
| Forward PE | n/a |
| Dividend | 1.50 (0.25%) |
| Ex-Dividend Date | Jul 30, 2024 |
| Volume | 3,034,769 |
| Open | 586.35 |
| Previous Close | 586.70 |
| Day's Range | 585.10 - 607.90 |
| 52-Week Range | 386.55 - 721.00 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 7, 2025 |
About Granules India
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules Ind... [Read more]
Financial Performance
In 2023, Granules India's revenue was 45.06 billion, a decrease of -0.12% compared to the previous year's 45.12 billion. Earnings were 4.05 billion, a decrease of -21.54%.
Financial StatementsNews
Granules India large trade: 1.3% equity worth Rs 191 crore changes hands
Granules India witnessed a significant block deal today as 32 lakh shares, representing 1.3% of the company’s equity, were traded for ₹191 crore. The shares exchanged hands at a price of ₹596 per shar...
Granules India receives USFDA approval for Lisdexamfetamine Dimesylate Chewable tablets
Granules India Limited, a leading Indian pharmaceutical company, has announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the U.S. Food & Drug A...
Compliance issues at Granules India’s Gagillapur plant
Granules India Ltd's Gagillapur plant in Hyderabad receives an official action indicated (OAI) classification from the US FDA after significant compliance issues including microbial contamination and ...
Granules India says US FDA action may impact new product approvals, expect meet with FDA soon
Granules India provides an update regarding the US FDA’s classification of its Gagillapur facility under “Official Action Initiated” (OAI), as per the recent communication on December 3, 2024. This cl...
Granules India stock falls over 10% from day’s high as US FDA classifies inspection as “Official Action Indicated”
Shares of Granules India witnessed a decline of on Monday, trading at ₹563 after opening at ₹614.30. The stock’s downward movement comes in response to the latest announcement concerning the company’s...
Granules India’s Gagillapur facility receives OAI classification from US FDA
Granules India Ltd has provided a significant update regarding the recent US FDA inspection of its Gagillapur facility in Hyderabad, Telangana. As per the company’s communication on September 7, 2024,...
Granules India achieves SBTi approval for ambitious net-zero goals
Granules India Limited has received SBTi approval for their climate commitments, targeting a 42% reduction in emissions by 2030 and striving for net-zero GHG emissions across their operations by FY205...
Granules India’s Unit V facility in Andhra Pradesh gets US FDA EIR with NAI status
India Business News: HYDERABAD: Pharma player Granules India Limited on Friday said it has received an Establishment Inspection Report (EIR) from the US Food and Drug Admi.
Granules India shares surge 2% after US FDA grants ‘No Action Indicated’ status to Andhra Pradesh facility
Granules India shares surged more than 2% after the US FDA granted its Andhra Pradesh Unit V facility a ‘No Action Indicated’ (NAI) status. This designation follows a recent inspection, confirming tha...
Granules India’s Andhra Pradesh facility receives ‘No Action Indicated’ status from US FDA
Granules India Limited, a prominent pharmaceutical manufacturer, has achieved a significant milestone as it received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration...
Granules India Q2 FY25 Results: Revenue drops 19%, Net Profit declines 5% YoY
Granules India Limited, a prominent player in the pharmaceutical industry, has announced its financial results for the second quarter of FY25, reporting a mixed performance marked by a decline in both...
Granules India Q2 FY25 results: Stock jumps 2% ahead of result announcement
Granules India Limited saw its shares jumped 2% in the morning trade session, signalling strong investor interest ahead of the company’s much-anticipated Q2 FY25 earnings results. The shares opened at...
Stocks to Buy This Diwali: Granules India – Share India recommends with a target of ₹770, potential upside 26%
Granules India Ltd, a key player in the pharmaceutical industry, has been recommended by Share India with a buy range of ₹590-610 and a target price of ₹770, offering a potential upside of 26%. The co...
Granules India gets USFDA approval for Bupropion Hydrochloride Extended-Release tablets
Granules India has recently informed exchanges that the company received USFDA approval for Bupropion Hydrochloride Extended-Release Tablets, a medication for depression and seasonal affective disorde...
F&O Ban List for October 4: Granules India, Manappuram Finance, Bandhan Bank and more
As of October 4, 2024, the following stocks have entered the F&O ban period: When the open interest (OI) on a stock surpasses 95% of the market-wide position limits (MWPL), the stock’s futures and opt...
Pharma Stocks Update: Granules up 3.56%, Ajanta Pharma gains 2.24% while JB Chemicals drops 2.82%, Mankind Pharma down 1.40% in mixed pharma stock performance
Pharma stocks have shown mixed performance in today’s trading session, with some major players gaining ground while others face declines. As of now, here’s how key pharmaceutical stocks are performing...
F&O ban: ABFRL, Granules, Hindustan Copper, IEX, and Vodafone Idea exit ban [Sept 27, 2024]
In today’s futures and options (F&O) segment, there are no stocks under the ban list. Meanwhile, the following stocks have exited the F&O ban: Aditya Birla Fashion and Retail (ABFRL) Granules India (G...
Stock market news: Aarti Industries, Biocon, GNFC, Granules India among stocks in F&O ban list on September 20
Several stocks remain in the Futures and Options (F&O) ban period as their open interest (OI) has crossed 95% of the market-wide position limits (MWPL). These stocks will remain in the ban until their...
Granules India stock crashes after USFDA concerns
The USFDA issued six observations to Granules India's Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues prompt...
Granules India share dips 4% after receiving six observations from USFDA
Granules India’s stock declined 4% intraday on September 9 after the company got six observations from the US Food and Drug Administration. Granules India Limited recently informed exchanges that it h...
Granules India completes USFDA inspection at its Gagillapur facility
Granules India Limited recently informed exchanges that the company completed a US Food and Drug Administration (USFDA) inspection at its Gagillapur facility in Hyderabad, Telangana. The inspection, w...
Stock market news: Bandhan Bank, Granules, Hindustan Copper among stocks in F&O ban list on August 29
The National Stock Exchange (NSE) has placed the following securities under a trading ban in the futures and options (F&O) segment for August 29, 2024: BANDHANBNK (Bandhan Bank) GRANULES (Granules Ind...